Innovative Industrial Properties, Inc. Q1 FY2026 earnings call

• Regulatory Progress on Cannabis Rescheduling

  • The U.S. administration has moved state-licensed medical cannabis operations to Schedule 3 from Schedule 1, eliminating the 280E tax burden for all of the company's portfolio tenants, who hold medical licenses. Retrospective tax relief is also expected for qualifying operators.
  • Expedited DEA hearings on full rescheduling of all cannabis to Schedule 3 will begin June 29, 2026, with a final resolution expected within 30 days of the hearings starting.
  • At the state level, the Texas Compassionate Use Program awarded conditional licenses to two of the company's tenant partners, expanding opportunity in the growing Texas market.

• Portfolio & Leasing Activity

  • During Q1 2026, the company signed new leases for 4 properties totaling 331,000 square feet. Year-to-date through Q1, new leases total 389,000 square feet across 5 properties in California, Illinois, and Ohio, and one dispensary in Arizona was sold.
  • The company has resolved nearly all legacy assets from prior tenant defaults (Gold Flora, Pharmacan, Forefront): all 3 former Gold Flora properties (330,000 square feet total) are now fully leased; tentative agreements are in place for all 4 former Forefront properties (488,000 square feet total) pending regulatory and licensing approvals; two of the five former Pharmacan properties have been leased to new tenants (Grown Rogue and Curaleaf), with active negotiations or letters of intent in place for the remaining three.
  • The company reached a full litigation resolution with Pharmacan regarding prior lease defaults and will regain possession of returned properties by the end of May 2026. One tenant, Battle Green, defaulted on its lease in March 2026, and the company is pursuing eviction and other legal remedies.

• Capital & Balance Sheet Management

  • Year-to-date through Q1, the company raised $128 million in gross capital, consisting of $72 million in preferred equity, $36 million in common equity, and $20 million in 3-year secured fixed-rate debt at 9%. An additional ~$130 million in pending financings (including a $56.5 million 8.75% financing expected to close the day of the call) is in progress, with an expected blended rate just over 8% if completed.
  • As of March 31, 2026, total liquidity was ~$177 million ($89 million cash, $87.5 million available under revolving credit facilities). Credit metrics remain strong: debt service coverage ratio over 11x, net debt to adjusted EBITDA of 1.1x.

• Life Science Investment Update

  • The IQHQ investment is viewed as a long-term, high-yield strategic opportunity that diversifies the company's platform. The broader life science real estate market is stabilizing, with demand holding near pre-pandemic levels and improving venture funding supporting growth. While elevated vacancy remains from prior development waves, new construction has fallen to historic lows, creating a healthier long-term supply-demand balance.

The company operates two core business segments: cannabis-focused real estate and a life science investment segment centered on its commitment to IQHQ. For Q1 2026, total company revenue was $69 million, a 3.5% increase from Q4 2025. Total adjusted funds from operations (AFFO) was $53.4 million, or $1.88 per share, flat compared to Q4 2025. As of Q1 end, the company has funded $175 million of its $270 million total commitment to IQHQ, with the remaining $95 million scheduled for future drawdown. No separate revenue contribution percentages are provided for the two segments in the call.

Management provided the following forward-looking outlooks: • No specific financial guidance for full-year 2026 was issued, but management expects to complete all pending financing transactions to address the May 2026 unsecured bond maturity, and remains confident in the company's strong balance sheet position to support future growth. • The remaining $95 million of the $270 million IQHQ commitment will be drawn opportunistically through mid-20027, with some draws already pulled forward earlier than scheduled due to the attractive yield spread on the investment. • Pending tentative leases for former Forefront properties are expected to take effect after the conclusion of ongoing receivership proceedings, which management currently expects to complete by the end of 2026. Newly executed leases typically take 3 to 18 months to commence, depending on regulatory licensing timelines, though triple net operating expenses transfer to tenants immediately upon lease execution, providing an immediate boost to earnings. • Management expects that full resolution of 280E for all cannabis operators (following the June 2026 DEA hearings) will drive stronger tenant economics, increased expansion activity, and higher demand for the company's industrial cannabis real estate in the medium term.

• Forward-looking statements (including pending financing and leasing transactions) are subject to risks and uncertainties, and actual results may differ materially from expectations; completed financing is required to address the May 2026 bond maturity, and pending transactions remain subject to contingencies that may prevent closing.
• All tentative lease agreements and ongoing negotiations are subject to customary due diligence, regulatory licensing, and receivership approvals, and there is no assurance these will result in definitive, commenced leases.
• While 280E elimination is expected to improve overall tenant credit health, individual tenant credit issues and business failures will still occur, as in any other industry, which may lead to additional lease defaults and re-leasing costs.
• Persistent inflation, elevated interest rates, and broader macroeconomic headwinds continue to challenge the operating environment for both the company and its tenants.
• Full cannabis legalization and the introduction of widespread interstate commerce remains a long-term possibility that is not expected for many years, but would create uncertain competitive dynamics for existing in-state cultivation assets.

Q: An analyst asks what the timeline is for the 12 pending/unexecuted leases to commence contributing earnings, and what rent levels the new leases are achieving compared to the original prior rents. / A: Regan states that typical lease execution to commencement takes 3-18 months, after accounting for licensing transfers and free rent periods. Triple net expenses shift to the tenant immediately upon signing, so there is an immediate earnings contribution even before rent commences. The previously stated 0-50% rental range compared to prior leases still holds for all new re-leasing activity, and capital outlays to re-tenant are only $5-$10 per square foot, which is very low for the industry. The company has now addressed over 90% of all legacy defaulted assets via executed leases, LOIs, or active negotiations.

Q: An analyst asks whether 280E elimination for medical cannabis will fully eliminate future tenant credit issues for the portfolio. / A: Alan Gold explains that 280E relief will greatly improve the operating environment for tenants, but every industry has businesses that succeed and fail due to management quality and other competitive factors. The company will continue to experience occasional tenant credit issues just like any other diversified real estate firm.

Q: An analyst asks when the company plans to make future incremental investments in IQHQ preferred stock, and what the near-term acquisition priorities are for the cannabis portfolio. / A: Alan Gold notes the full $270 million IQHQ commitment is scheduled through mid-2027, and some draws have already been pulled forward opportunistically due to the attractive 14% yield against a 6% cost of capital. The company's top near-term priority is completing the pending refinancing of its upcoming unsecured bond maturity; once that and the IQHQ commitment are complete, the company will pursue new net cannabis acquisition opportunities, with a near-term focus on clear medical markets like Texas.

Q: An analyst asks whether Schedule 3 rescheduling will enable interstate cannabis commerce, and how that would impact the company's portfolio, as well as the impact of a potential federal ban on intoxicating hemp. / A: Paul Smithers replies that rescheduling does not address interstate commerce or banking, and full interstate commerce is not expected for many years until full federal legalization. Even if interstate commerce is implemented, the company's portfolio of specialized indoor medical cultivation assets is well-positioned to compete. The company's tenants do not grow hemp, and a ban on intoxicating hemp would bring regulatory clarity and remove unregulated competition, which is a positive outcome for the company's licensed cannabis tenants.